MDT

83.87

+0.59%↑

VEEV

220.35

+2.08%↑

A

105.08

+2.22%↑

WBA

10.98

0%↓

CHE

587.63

+1.41%↑

MDT

83.87

+0.59%↑

VEEV

220.35

+2.08%↑

A

105.08

+2.22%↑

WBA

10.98

0%↓

CHE

587.63

+1.41%↑

MDT

83.87

+0.59%↑

VEEV

220.35

+2.08%↑

A

105.08

+2.22%↑

WBA

10.98

0%↓

CHE

587.63

+1.41%↑

MDT

83.87

+0.59%↑

VEEV

220.35

+2.08%↑

A

105.08

+2.22%↑

WBA

10.98

0%↓

CHE

587.63

+1.41%↑

MDT

83.87

+0.59%↑

VEEV

220.35

+2.08%↑

A

105.08

+2.22%↑

WBA

10.98

0%↓

CHE

587.63

+1.41%↑

Search

CytoSorbents Corp

Fechado

SetorSaúde

1.06 1.92

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.02

Máximo

1.08

Indicadores-chave

By Trading Economics

Rendimento

-5.5M

-7.9M

Vendas

538K

9.2M

EPS

-0.144

Margem de lucro

-86.158

Funcionários

149

EBITDA

-4.6M

-8.5M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

-8.26% downside

Dividendos

By Dow Jones

Próximos Ganhos

8 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

5.8M

68M

Abertura anterior

-0.86

Fecho anterior

1.06

Sentimento de Notícias

By Acuity

50%

50%

181 / 382 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

CytoSorbents Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

23 de abr. de 2025, 23:54 UTC

Ações em Alta

Stocks to Watch: International Business Machines, Southwest Airlines, Robert Half

23 de abr. de 2025, 23:23 UTC

Principais Notícias
Ganhos

SK Hynix Posts Strong First Quarter Earnings on AI Chip Demand

23 de abr. de 2025, 21:06 UTC

Ganhos

Lam Research Notches Higher 3Q Profit and Revenue, Optimistic 4Q Outlook

23 de abr. de 2025, 21:03 UTC

Ganhos

Texas Instruments Posts Increase in 1Q Sales, EPS

24 de abr. de 2025, 00:00 UTC

Ganhos

Renesas Electronics 1Q Net Y26.01B Vs Net Y79.87B

24 de abr. de 2025, 00:00 UTC

Ganhos

Renesas Electronics 1Q Net Y26.01B Vs Net Y79.87B

23 de abr. de 2025, 23:47 UTC

Conversa de Mercado

Gold Rises Amid Lingering Uncertainty Over U.S.-China Trade War -- Market Talk

23 de abr. de 2025, 23:44 UTC

Conversa de Mercado

Nikkei May Rise as Fears About U.S. Tariffs Ease -- Market Talk

23 de abr. de 2025, 23:44 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

23 de abr. de 2025, 23:37 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

23 de abr. de 2025, 23:36 UTC

Conversa de Mercado

Fed Should Have a 'High Bar' to Intervene in Markets, Hammack Says -- Market Talk

23 de abr. de 2025, 23:21 UTC

Conversa de Mercado

Northern Star Bull Says Share Price Accounts for Operational Risks -- Market Talk

23 de abr. de 2025, 23:00 UTC

Principais Notícias

South Korea's Economy Shrinks in 1Q Before Trump Tariffs Hit

23 de abr. de 2025, 22:51 UTC

Ganhos

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

23 de abr. de 2025, 22:50 UTC

Ganhos

SK Hynix 1Q Net KRW8.108T Vs. Net KRW1.917T >000660.SE

23 de abr. de 2025, 22:49 UTC

Ganhos

SK Hynix 1Q Oper Pft KRW7.441T Vs. Pft KRW2.886T >000660.SE

23 de abr. de 2025, 22:49 UTC

Ganhos

SK Hynix 1Q Rev KRW17.639T Vs. KRW12.430T >000660.SE

23 de abr. de 2025, 22:32 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Global Energy Roundup: Market Talk

23 de abr. de 2025, 22:32 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Woodside Appears Cornered Into 2Q Decision on Louisiana LNG -- Market Talk

23 de abr. de 2025, 22:29 UTC

Conversa de Mercado
Ganhos

ServiceNow CEO Says Aptiv Deal Marks 2nd Largest in EMEA -- Market Talk

23 de abr. de 2025, 22:18 UTC

Ganhos

CGN Power: 1Q Net Weighed by Fall in Electricity Prices, Higher R&D Expenses >1816.HK

23 de abr. de 2025, 22:17 UTC

Ganhos

CGN Power 1Q Net CNY3.03B Vs. Net CNY3.60B >1816.HK

23 de abr. de 2025, 22:17 UTC

Ganhos

CGN Power 1Q Rev CNY20.03B Vs. CNY19.18B >1816.HK

23 de abr. de 2025, 21:57 UTC

Conversa de Mercado
Ganhos

ServiceNow Earnings, Guidance Soothe Fear of Slower Govt Business -- Market Talk

23 de abr. de 2025, 21:48 UTC

Principais Notícias

Shingles Vaccine Appears to Lower Dementia Risk -- WSJ

23 de abr. de 2025, 21:14 UTC

Principais Notícias
Ganhos

Southwest Airlines Drops Forecast as Leisure Travelers Pull Back -- WSJ

23 de abr. de 2025, 21:05 UTC

Ganhos

Texas Instruments Reports Strong Earnings. The Stock Is Rising but Tariffs Are Still a Risk. -- Barrons.com

23 de abr. de 2025, 21:02 UTC

Principais Notícias

Huge Stock Swings Are the New Normal for Frazzled Investors -- WSJ

23 de abr. de 2025, 20:51 UTC

Ganhos

Boeing Stock Surges on Earnings. There Is Still a Lot of Uncertainty Ahead. -- Barrons.com

23 de abr. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

Comparação entre Pares

Variação de preço

CytoSorbents Corp Previsão

Preço-alvo

By TipRanks

-8.26% parte inferior

Previsão para 12 meses

Média 1 USD  -8.26%

Máximo 1 USD

Mínimo 1 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para CytoSorbents Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

1 ratings

0

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

0.827 / N/ASuporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

181 / 382 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.